| scholarly article | Q13442814 |
| P2093 | author name string | Mithun J Varghese | |
| P2860 | cites work | Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents: Summary Report | Q22305957 |
| Statins for children with familial hypercholesterolemia | Q24234081 | ||
| Dietary treatment for familial hypercholesterolaemia | Q24240324 | ||
| Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study | Q24645376 | ||
| Monogenic hypercholesterolemia: new insights in pathogenesis and treatment | Q24672834 | ||
| Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group | Q24675141 | ||
| Familial hypercholesterolemia: present and future management | Q26828489 | ||
| Autosomal recessive hypercholesterolaemia in Sardinia, Italy, and mutations in ARH: a clinical and molecular genetic analysis | Q28207619 | ||
| Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial | Q28273112 | ||
| Simvastatin with or without ezetimibe in familial hypercholesterolemia | Q28274454 | ||
| Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia | Q28282776 | ||
| A systematic review of bile acid sequestrant therapy in children with familial hypercholesterolemia | Q28307021 | ||
| Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice | Q28588849 | ||
| Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption | Q28593100 | ||
| Sequence variations in PCSK9, low LDL, and protection against coronary heart disease | Q29616310 | ||
| Long-term safety and efficacy of a cholesterol-lowering diet in children with elevated low-density lipoprotein cholesterol: seven-year results of the Dietary Intervention Study in Children (DISC). | Q31832750 | ||
| Distributions and trends of serum lipid levels among United States children and adolescents ages 4-19 years: data from the Third National Health and Nutrition Examination Survey | Q31919181 | ||
| Effect of a monoclonal antibody to PCSK9 on LDL cholesterol | Q34262650 | ||
| LDLR-Gene therapy for familial hypercholesterolaemia: problems, progress, and perspectives | Q34467839 | ||
| Recommendations for the use of LDL apheresis | Q34655985 | ||
| Hypercholesterolemic valvulopathy: an aspect of malignant atherosclerosis | Q35187630 | ||
| Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia | Q35791930 | ||
| Current management of severe homozygous hypercholesterolaemias | Q35830954 | ||
| Familial hypercholesterolaemia: summary of NICE guidance | Q57316582 | ||
| Risk of Fatal Stroke in Patients With Treated Familial Hypercholesterolemia | Q57321423 | ||
| Drug Therapy of High-Risk Lipid Abnormalities in Children and Adolescents | Q57414115 | ||
| American Academy of Pediatrics. National Cholesterol Education Program: Report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents | Q68062375 | ||
| Natural history and cardiac manifestations of homozygous familial hypercholesterolaemia | Q68567438 | ||
| Cardiovascular features of homozygous familial hypercholesterolemia: Analysis of 16 patients | Q70221252 | ||
| Lipid and lipoprotein distributions in white children ages 6-19 yr. The Lipid Research Clinics Program Prevalence Study | Q71440737 | ||
| Neonatal diagnosis of familial hypercholesterolemia in newborns born to a parent with a molecularly defined heterozygous familial hypercholesterolemia | Q73966014 | ||
| The rebound of lipoproteins after LDL-apheresis. Kinetics and estimation of mean lipoprotein levels | Q74348259 | ||
| Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group | Q77750545 | ||
| Trends in the prevalence of chronic medication use in children: 2002-2005 | Q79771692 | ||
| High prevalence of major cardiovascular risk factors in first-degree relatives of individuals with familial premature coronary artery disease--the GENECARD project | Q80242091 | ||
| Storm over statins--the controversy surrounding pharmacologic treatment of children | Q82061154 | ||
| Liver transplantation as a treatment option for three siblings with homozygous familial hypercholesterolemia | Q83207278 | ||
| Pediatric aspects of familial hypercholesterolemias: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia | Q84159263 | ||
| Reduced penetrance of autosomal dominant hypercholesterolemia in a high percentage of families: importance of genetic testing in the entire family | Q84829637 | ||
| Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia | Q85324637 | ||
| Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study | Q36104706 | ||
| Statin treatment for children and adolescents with heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis | Q36650396 | ||
| Lipid screening and cardiovascular health in childhood | Q37205462 | ||
| Systematic review and metaanalysis of statins for heterozygous familial hypercholesterolemia in children: evaluation of cholesterol changes and side effects | Q37384379 | ||
| Ezetimibe treatment of pediatric patients with hypercholesterolemia | Q37397310 | ||
| Low-density lipoprotein apheresis as a treatment option for hyperlipidemia | Q37559897 | ||
| Evaluation and management of hyperlipidemia in children and adolescents. | Q37771233 | ||
| Redefining normal low-density lipoprotein cholesterol: a strategy to unseat coronary disease as the nation's leading killer | Q37779637 | ||
| Preemptive liver transplantation in a child with familial hypercholesterolemia | Q37789441 | ||
| Severe hypercholesterolaemia: therapeutic goals and eligibility criteria for LDL apheresis in Europe | Q37799233 | ||
| Lipoprotein apheresis | Q37826065 | ||
| Long-term follow-up of statin treatment in a cohort of children with familial hypercholesterolemia: efficacy and tolerability | Q37892524 | ||
| Management of familial hypercholesterolemia in children and young adults: consensus paper developed by a panel of lipidologists, cardiologists, paediatricians, nutritionists, gastroenterologists, general practitioners and a patient organization. | Q37901641 | ||
| Defining the role of lipoprotein apheresis in the management of familial hypercholesterolemia | Q37965588 | ||
| Screening for familial hypercholesterolaemia. | Q37974123 | ||
| Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment | Q37991466 | ||
| Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery dis | Q38462674 | ||
| Relevance of genetics and genomics for prevention and treatment of cardiovascular disease: a scientific statement from the American Heart Association Council on Epidemiology and Prevention, the Stroke Council, and the Functional Genomics and Transla | Q40211418 | ||
| Familial hypercholesterolaemia | Q41779360 | ||
| Primary hyperlipidemias in children: effect of plant sterol supplementation on plasma lipids and markers of cholesterol synthesis and absorption | Q42681184 | ||
| Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial | Q43130496 | ||
| Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia | Q43134690 | ||
| Genetics and kinetics of familial hypercholesterolemia, with the special focus on FH-(Marburg) p.W556R. | Q43175159 | ||
| Colesevelam hydrochloride: efficacy and safety in pediatric subjects with heterozygous familial hypercholesterolemia | Q43251340 | ||
| Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands. | Q43264146 | ||
| Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study | Q43418707 | ||
| Effects of nonlipid risk factors on atherosclerosis in youth with a favorable lipoprotein profile | Q43546643 | ||
| Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis | Q43638006 | ||
| Risks of ischaemic heart-disease in familial hyperlipoproteinaemic states | Q43924064 | ||
| Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia | Q44009231 | ||
| Intravascular ultrasound evaluation of coronary plaque regression by low density lipoprotein-apheresis in familial hypercholesterolemia: the Low Density Lipoprotein-Apheresis Coronary Morphology and Reserve Trial (LACMART). | Q44054756 | ||
| Effects of plant stanol and sterol esters on serum phytosterols in a family with familial hypercholesterolemia including a homozygous subject | Q44845251 | ||
| Long-term compliance and changes in plasma lipids, plant sterols and carotenoids in children and parents with FH consuming plant sterol ester-enriched spread | Q44938378 | ||
| Virus treatment questioned after gene therapy death | Q45746742 | ||
| Efficacy and safety of coadministration of ezetimibe and simvastatin in adolescents with heterozygous familial hypercholesterolemia | Q46305487 | ||
| Infusion of reconstituted high-density lipoprotein leads to acute changes in human atherosclerotic plaque. | Q46333846 | ||
| Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy | Q46408437 | ||
| Update and analysis of the University College London low density lipoprotein receptor familial hypercholesterolemia database | Q46715028 | ||
| Autosomal recessive hypercholesterolemia (ARH) and homozygous familial hypercholesterolemia (FH): a phenotypic comparison | Q46847101 | ||
| Coronary artery disease in 116 kindred with familial type II hyperlipoproteinemia | Q47889721 | ||
| Relation of serum lipoprotein levels and systolic blood pressure to early atherosclerosis. The Bogalusa Heart Study. | Q53892360 | ||
| Binding and degradation of low density lipoproteins by cultured human fibroblasts. Comparison of cells from a normal subject and from a patient with homozygous familial hypercholesterolemia. | Q54261784 | ||
| Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. | Q55054280 | ||
| Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics | Q57309575 | ||
| Mutation detection rate and spectrum in familial hypercholesterolaemia patients in the UK pilot cascade project | Q57316565 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hypercholesterolemia | Q762713 |
| familial hypercholesterolemia | Q2711291 | ||
| P304 | page(s) | 107-117 | |
| P577 | publication date | 2014-05-01 | |
| P1433 | published in | Annals of Pediatric Cardiology | Q4767857 |
| P1476 | title | Familial hypercholesterolemia: A review | |
| P478 | volume | 7 |
| Q35761096 | A Splice Region Variant in LDLR Lowers Non-high Density Lipoprotein Cholesterol and Protects against Coronary Artery Disease |
| Q51758610 | Advances in Pathophysiology of Calcific Aortic Valve Disease Propose Novel Molecular Therapeutic Targets. |
| Q37733136 | Antisense Oligonucleotides: Treatment Strategies and Cellular Internalization |
| Q36836059 | Development of Aortic Valve Disease in Familial Hypercholesterolemic Swine: Implications for Elucidating Disease Etiology |
| Q64052968 | Development of a Synthetic 3-ketosteroid Δ-dehydrogenase for the Generation of a Novel Catabolic Pathway Enabling Cholesterol Degradation in Human Cells |
| Q42430542 | Expert and Advocacy Group Consensus Findings on the Horizon of Public Health Genetic Testing |
| Q55284678 | Familial hypercholesterolemia. |
| Q26770143 | Familial hypercholesterolemia: Review of diagnosis, screening, and treatment |
| Q39152643 | Genetic, hematological, and immunological disorders transmissible with liver transplantation |
| Q35850911 | Impact of cholesterol on disease progression |
| Q38872573 | Liver transplantation for pediatric inherited metabolic disorders: Considerations for indications, complications, and perioperative management |
| Q37692662 | Low-density lipoprotein apheresis in a pediatric patient of familial hypercholesterolemia: Primi experientia from a tertiary care center in North India |
| Q47098216 | New Treatments on the Horizon for Familial Hypercholesterolemia |
| Q47099946 | Post-transcriptional Regulation of PCSK9 by miR-191, miR-222, and miR-224. |
| Q41544724 | Prevention of cardiovascular disease in patients with familial hypercholesterolaemia: The role of PCSK9 inhibitors |
| Q35690502 | The Challenge of Cardiovascular Diseases and Diabetes to Public Health: A Study Based on Qualitative Systemic Approach |
| Q50084571 | The extending spectrum of NPC1-related human disorders: from Niemann-Pick C1 Disease to obesity |
| Q46840217 | Hypercholestérolémie familiale: Révision du diagnostic, du dépistage et du traitement |
Search more.